Article
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
31 May 2011
Abstract excerpt
Abstract Learning Objectives After completing this course, the reader will be able to: Explain the IC50 of a tyrosine kinase inhibitor and the kind of information this parameter provides about its efficacy.List the multiple factors that may be responsible for resistance to a target therapeutic agent.Describe the clinical relevance of Bcr-Abl mutations in chronic myeloid leukemia patients. This article is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.